Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Seres Therapeutics ( (MCRB) ) is now available.
Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Science, enhancing its financial standing and honing its focus on developing live biotherapeutics for patients at high risk of severe bacterial infections. The deal includes an immediate cash payment and potential future milestone payments, based on VOWST’s net sales, totaling up to $275 million. Additionally, Seres will provide transition services to facilitate the business handover, while retaining a non-exclusive license to certain intellectual property. The agreement also involves SPN’s purchase of Seres’ common stock and an employee support arrangement to ensure a smooth transition.
See more data about MCRB stock on TipRanks’ Stock Analysis page.
